- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
MTF Biologics and Kolosis BIO Launch New DBX Fiber Product
The latest addition to the DBX family of biomaterials aims to advance regenerative medicine solutions.
Mar. 31, 2026 at 7:54pm
Got story updates? Submit your updates here. ›
The launch of the new DBX Fiber biomaterial product showcases the continued innovation in regenerative medicine technologies.Salt Lake City TodayMTF Biologics, a leading tissue bank, and Kolosis BIO, a biotechnology company, have announced the launch of the latest product in their DBX family of biomaterials - the DBX Fiber. The new DBX Fiber is designed to support tissue regeneration and repair, expanding the companies' portfolio of innovative solutions for the regenerative medicine market.
Why it matters
The launch of the DBX Fiber represents an important milestone for MTF Biologics and Kolosis BIO, as they continue to drive advancements in regenerative medicine technologies. The new product is expected to provide healthcare providers with an additional tool to support patient healing and recovery, potentially improving outcomes for a range of medical procedures.
The details
The DBX Fiber is a next-generation biomaterial that combines the proven performance of the existing DBX portfolio with a unique fiber-based structure. This innovative design is intended to enhance the material's handling characteristics and facilitate easier application during surgical procedures. The DBX Fiber is derived from donated human tissue and is processed using the companies' proprietary technologies to preserve the natural properties of the source material.
- MTF Biologics and Kolosis BIO announced the launch of the DBX Fiber on March 31, 2026.
The players
MTF Biologics
A leading tissue bank that specializes in the recovery, processing, and distribution of donated human tissue for use in medical procedures.
Kolosis BIO
A biotechnology company that partners with MTF Biologics to develop innovative biomaterial solutions for the regenerative medicine market.
What they’re saying
“We are excited to introduce the DBX Fiber as the latest addition to our growing portfolio of regenerative medicine products. This new biomaterial further demonstrates our commitment to providing healthcare providers with advanced solutions that can enhance patient outcomes.”
— Joe Yaccarino, President and CEO of MTF Biologics
“The DBX Fiber represents a significant advancement in our efforts to develop innovative biomaterials that can support the body's natural healing processes. We believe this product will be a valuable tool for clinicians working to improve patient care and quality of life.”
— Dr. Sarah Lim, Chief Scientific Officer of Kolosis BIO
What’s next
MTF Biologics and Kolosis BIO plan to showcase the DBX Fiber at the upcoming Regenerative Medicine Conference in June 2026, where they will provide more details on the product's features and potential applications.
The takeaway
The launch of the DBX Fiber by MTF Biologics and Kolosis BIO underscores the ongoing advancements in regenerative medicine technologies. This new biomaterial product is expected to expand the options available to healthcare providers, potentially leading to improved patient outcomes and accelerated healing.
